Navigation Links
Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Date:4/21/2011

ion of a May 12th consent deadline underscores the conclusion that Valeant is trying to rush Cephalon shareholders into a decision that may not be in your best interests
  • This is all about value for Cephalon shareholders – your current Board is best positioned to consider the Valeant non-binding proposal, is presently undertaking a review of all of Cephalon's alternatives and options and is focused on maximizing value for all Cephalon shareholders

  • Protect the value of your investment.  Do not consent to Valeant's attempt to put its hand-picked slate on your Board.  Maximize the value of your shares by supporting your current Board of Directors – please sign, date and mail the enclosed WHITE Consent Revocation Card immediately.VALEANT'S $73 PER SHARE PROPOSAL IS INADEQUATE AND NOT IN YOUR BEST INTERESTSThe Board has determined that Valeant's proposed price significantly undervalues the Company, including the greater value the Board believes is achievable from the Company's strategic plan, especially the value of the Company's diversified portfolio of marketed and pipeline products in the therapeutic areas of CNS, pain, oncology, immunology and regenerative medicine.  

    By Valeant's own admission, its analysis of Cephalon's value is based on a worst-case scenario for Cephalon, which the Board believes is an inappropriate methodology.  Even with this approach, Valeant's chief executive officer confidently noted during an investor conference call on March 30, 2011 that Valeant's proposal minimizes downside value risk for Valeant and its shareholders even if all of Valeant's worst-case scenario assumptions for Cephalon's business are realized.

    You should be aware that:

  • The 30-day average Cephalon share price of $56.74 on which Valeant based its non-binding proposal is near the stock's 52-week low and Valeant's non-binding proposal represents virtually no premium to Cephalon's 52-week high.
  • '/>"/>

    SOURCE Cephalon, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cephalon Quarterly Conference Call Invitation
    2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
    3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
    4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
    5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
    6. Cephalon Reports Another Strong Quarter
    7. Cephalon, Inc. to Webcast Analyst Day
    8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
    9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
    10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
    11. Cephalons New Product Launches Pace Record 2008 Sales
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
    (Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
    (Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
    (Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
    Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
    ... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company ... to regress atherosclerotic plaque, announced the recent presentation ... Division of Cardiology at the David Geffen School ... Heart Association (AHA) Scientific Sessions in Orlando, Florida.  ...
    ... 2011  If algae is to be the solution for America,s ... make that a reality. Applications are now available for continuing ... retrain workers as general science technicians in the rapidly expanding ... Approximately 55 students will begin classes in ...
    ... 22, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... announced the Company,s participation at the 23rd Annual Piper Jaffray ... November 29-30, 2011. Ronald M. Lindsay, Ph.D., ... Maier, CFO, will present on Tuesday, November 29, 2011 beginning ...
    Cached Biology Technology:AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2
    (Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
    (Date:8/19/2014)... The University of Texas Health Science Center at San ... (UTSA) today announced the awarding of more than $750,000 ... (SALSI) Innovation Challenge. , Launched in 2003, SALSI is ... and an academic health science center join forces for ... funds collaborative studies, with a focus on public health ...
    (Date:8/19/2014)... has been awarded a nearly $40,000 grant from the ... office of the National Park Service (NPS) and U.S. ... one-year study of the energy efficiency and cost effectiveness ... humid climates. , Radiant barriers are reflective thermal insulations ... back, thereby reducing the amount of heat emitted in ...
    Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
    ... vegetative cover, strong winds, dry, non-cohesive sandy soils, ... resources of Abu Dhabi Emirate in the United ... stresses, including wind erosion, salinization, waterlogging, landfilling, and ... Dhabi Emirate, land degradation is a matter of ...
    ... have found a way to save time, money and ... shed light on the biological processes associated with all ... genetics, and postdoctoral associate Matthew C. Hale have provided ... necessary with recent advances in DNA sequencing technology. Instead, ...
    ... Pfizer Inc., a major biopharmaceutical company, and the Wisconsin ... licensing organization for the University of Wisconsin-Madison, announced May ... embryonic stem (hES) cell patents for the development of ... the rights to work with hES cells for drug ...
    Cached Biology News:Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2Random picks better than complicated process in gene identification 2WARF signs license agreement with Pfizer for human embryonic stem cells 2
    ... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
    ... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
    ... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
    ...
    Biology Products: